“GLP-1s make your birth control fail.”
What the evidence shows
This is a labeled, well-established difference between two drugs people lump together. Tirzepatide (Mounjaro, Zepbound) delays gastric emptying enough to blunt absorption of pills swallowed at the same time: in pharmacokinetic studies a single dose cut the peak blood level of the contraceptive estrogen by more than half, and the FDA label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. The effect is largest right after starting and after a dose step-up, then fades — which is why the label ties the backup window to those moments.
What we still don’t know
The exact real-world failure rate for someone who ignores the tirzepatide backup guidance isn't quantified. And the warning is specific: it applies to swallowed pills, because that's the route gastric emptying affects. Non-oral methods (implant, IUD, injection, patch, vaginal ring) don't depend on gut absorption and are not the label's concern — in fact the label points to a non-oral method as the fix.
Why the claim misleads
Generalizing 'GLP-1s make birth control fail' to every drug and every method is wrong in both directions. Semaglutide (Ozempic, Wegovy, Rybelsus) did not show a clinically meaningful effect on oral-contraceptive absorption and carries no backup-contraception instruction, so applying tirzepatide's warning to it can make people needlessly anxious. Meanwhile someone on tirzepatide using the pill could under-protect if they assume the caution doesn't apply to them. The precise, useful version: on tirzepatide plus the pill, plan a backup or non-oral method with a prescriber before starting.
Graded by The Peptide Era · evidence, not hype